American Well CORP

American Well Corporation announced a director reclassification to maintain balanced board classes as required by NYSE listing standards.

American Well Corporation announced the immediate resignation of Dr. Roy Schoenberg from its Board of Directors due to a new employment opportunity.

Dr. Peter Slavin is resigning from the American Well Corporation Board of Directors effective at the company's 2026 annual meeting, citing a move to the West Coast.

Amwell announced its fourth quarter and full year 2025 financial results, exceeding Q4 revenue guidance and outlining a path to positive cash flow from operations by Q4 2026.

American Well Corporation has renewed and expanded its strategic partnership with Elevance Health, Inc. for its LiveHealth Online digital care delivery platform through January 2029.

American Well Corporation has extended its Master Services Agreement and related provider agreements with Elevance Health, securing a multi-year partnership for its digital care platform and clinical services.

American Well Corporation reported a 18% revenue decrease in Q1 2026 compared to the prior year, driven by lower subscription and other revenues, alongside significant cost-cutting measures.

Amwell reported a significant reduction in net loss and improved Adjusted EBITDA for Q3 and the first nine months of 2025, driven by strategic cost-cutting and increased subscription revenue.

Amwell reported significantly reduced net losses and strong subscription revenue growth in Q2 2025, driven by strategic divestitures and cost-cutting measures.

American Well Corporation (Amwell) announces its Q1 2025 financial results, highlighting a 12% increase in revenue and strategic adjustments including the divestiture of Aligned Telehealth.

American Well Corporation's third quarter 2024 results show a slight revenue decrease and a net loss, as the company continues its strategic transformation and platform migration.

American Well Corporation's Q2 2024 results show flat revenue year-over-year as the company continues its platform transition.

American Well Corporation's 2024 10-K filing reveals a company in transition, focusing on its Converge platform and strategic partnerships while navigating losses and market volatility.

American Well Corporation filed an amendment to its annual report to correct a typographical error in the signing date of the independent auditor's report.

Amwell's 2023 10-K filing highlights its focus on hybrid care through its Converge platform, with a significant increase in visits on the new platform and ongoing client migration efforts.

Paul McNeice, Chief Accounting Officer of American Well Corp, sold 653 shares of Class A Common Stock for $9.33 per share to cover tax liabilities from vested restricted stock units.

American Well Corp's Chief Financial Officer, Mark Hirschhorn, sold 4,299 shares of Class A Common Stock on July 1, 2026, to cover tax liabilities from vested restricted stock units.

American Well Corp. Chief Product & Tech Officer Dmitry Zamansky sold 8,460 shares of Class A Common Stock for $9.33 per share to cover tax liabilities from vested restricted stock units.

Phyllis Gotlib, President of International at American Well Corp, reported a sale of 6,677 shares of Class A Common Stock to cover tax liabilities from vested restricted stock units.

Director Delos M. Cosgrove acquired 14,501 shares of Class A Common Stock in American Well Corp.

American Well Corp director Robert Webb acquired 14,501 restricted stock units, vesting over one year, as detailed in a Form 4 filing.

American Well Corporation announces its 2026 Annual Meeting of Stockholders, highlighting strategic progress, financial performance, and corporate governance matters.

American Well Corporation (Amwell) has announced its annual meeting of stockholders to be held on June 18, 2024, and is providing details on how stockholders can vote on key proposals.

Amwell Corporation outlines its strategic focus on growth, recurring revenue, and efficiency to achieve positive cash flow by 2026, leveraging its unified technology-enabled care platform.

American Well Corporation (Amwell) is holding its annual meeting on June 18, 2024, seeking stockholder approval for the election of directors, ratification of the auditor, executive compensation, and a reverse stock split.

Amwell's proxy statement highlights the company's strategic achievements in 2023, including platform migration and market wins, while outlining priorities for 2024 focused on profitable growth and continued platform development.

Senvest Management, LLC and Richard Mashaal have reported a beneficial ownership of 7.6% in American Well Corp's Class A Common Stock as of March 31, 2026.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have filed an amended Schedule 13G, reporting beneficial ownership of 7.8% and 7.7% of American Well Corp's Class A Common Stock, respectively.

Ido and Roy Schoenberg, co-founders of American Well Corp, have jointly disclosed beneficial ownership representing 51% of the company's total voting power through a voting agreement.

Senvest Management, LLC and Richard Mashaal have increased their beneficial ownership in American Well Corp to 5.0% of Class A Common Stock.

Funicular Funds, LP, along with Cable Car Capital, LP and Jacob Ma-Weaver, has reported a passive 5.5% beneficial ownership stake in American Well Corp's Class A Common Stock.

Caledonia (Private) Investments Pty Limited and Caledonia US, LP have reduced their beneficial ownership in American Well Corp's Class A Common Stock to 4.35%.